Details of Drug Interaction | MecDDI

Drug General Information (ID: DDITOBY15E)
Drug Name			Cyclosporine		Drug Info		Itraconazole		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiviral Agents				Antifungal Agents
Structure

Mechanism of Cyclosporine-Itraconazole Interaction (Severity Level: Major)
CYP450 enzyme inhibition Click to Show/Hide Mechanism Graph

Drug Name		Cyclosporine				Itraconazole
Mechanism		CYP450 3A4 substrate				CYP450 3A4 inhibitor
Key Mechanism Factor 1
		Factor Name		Cytochrome P450 3A4				× Structure Sequence MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA
		Gene Name		CYP3A4
		Uniprot ID		CP3A4_HUMAN
		KEGG Pathway		hsa:1576
		Protein Family		Cytochrome P450 family
		Protein Function		A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:20702771, PubMed:19965576, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:2732228, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:21576599, PubMed:21490593). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:14559847, PubMed:12865317). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:2732228, PubMed:15373842, PubMed:15764715, PubMed:22773874). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:2732228, PubMed:15373842, PubMed:15764715). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981). Click to Show/Hide
Mechanism Description		Decreased metabolism of Cyclosporine caused by Itraconazole mediated inhibition of CYP450 enzyme

Recommended Action
Management		Cyclosporine dosage reductions are often necessary during coadministration with azole antifungal agents. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of antifungal therapy in patients who are stabilized on their cyclosporine regimen. A 60% to 80% reduction may be necessary during concomitant therapy with ketoconazole. Some authorities recommend reducing the dose of cyclosporine by 50% when coadministered with itraconazole at doses greater than 100 mg daily (AU). Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Charles BG, Ravenscroft PJ, Rigby RJ "The ketoconazole-cyclosporin interaction in an elderly renal transplant patient." Aust N Z J Med 19 (1989): 292-3. [PMID: 2673179]
4	First MR, Schroeder TJ, Alexander JW, et al "Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients." Transplantation 51 (1991): 365-70. [PMID: 1994529]
5	Gerntholtz T, Pascoe MD, Botha JF, Halkett J, Kahn D "The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries." Eur J Clin Pharmacol (2004):. [PMID: 15083250]
6	Horton CM, Freeman CD, Nolan PE Jr, Copeland JG 3rd "Cyclosporine interactions with miconazole and other azole- antimycotics: a case report and review of the literature." J Heart Lung Transplant 11 (1992): 1127-32. [PMID: 1457436]
7	Hwang WL, Gau JP, Young JH, Chia LG "Ketoconazole and high-dose methylprednisolone predisposing to cyclosporine-induced seizures: report of 3 cases." Acta Haematol 88 (1992): 139-41. [PMID: 1466196]
8	Keogh A, Spratt P, McCosker C, Macdonald, Mundy J, Kaan A "Ketoconazole to reduce the need for cyclosporine after cardiac transplantation." N Engl J Med 333 (1995): 628-33. [PMID: 7637723]
9	Kiss D, Thiel G "Glucose-intolerance and prolonged renal-transplant insufficiency due to ketoconazole-cyclosporin A interaction." Clin Nephrol 33 (1990): 207-8. [PMID: 2350909]
10	Kramer MR, Marshall SE, Denning DW, et al "Cyclosporine and itraconazole interaction in heart and lung transplant recipients." Ann Intern Med 113 (1990): 327-9. [PMID: 2165371]
11	Sobh M, Elagroudy A, Moustafa F, Harras F, Elbedewy M, Ghoneim M "Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study." Am J Nephrol 15 (1995): 493-9. [PMID: 8546171]
12	Sorenson AL, Lovdahl M, Hewitt JM, et al. "Effects of ketoconazole on cyclosporine metabolism in renal allograft recipients." Transplant Proc 26 (1994): 2822. [PMID: 7940888]
13	Yee GC, McGuire TR "Pharmacokinetic drug interactions with cyclosporin (Part I)." Clin Pharmacokinet 19 (1990): 319-32. [PMID: 2208899]